Ivanova, Elizaveta,
Asadullina, Dilara,
Gilyazova, Gulshat,
Rakhimov, Radmir,
Izmailov, Adel,
Pavlov, Valentin,
Khusnutdinova, Elza,
Gilyazova, Irina (2023) Immunotherapy with
immune checkpoint inhibitors (ICIs) has shown high efficiency in
clear cell
Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) prognosis and difficult to treat. Despite significant advances in the treatment of ccRCC,
immune checkpointIvanova, E.,
Asadullina, D.,
Rakhimov, R.,
Izmailov, A.,
Izmailov, Al.,
Gilyazova, G.,
Galimov, Sh.,
Pavlov, V.,
Khusnutdinova, E.,
Gilyazova, I. (2022) related toxicity.
Immune-related adverse events (irAEs) are a major cause of
immune checkpoint inhibitors
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа, a promising direction is NF1 therapy with STAT3 inhibitors and
immune checkpoint inhibitors
of activating the
immune response against tumor cells. Clinically used
checkpoint inhibition using antibodies